Exelixis touted last month that its Cabometyx proved so successful in neuroendocrine tumors (NETs) that the trial ended early. Now, we get to see what one analyst had already heralded as the “dramatic ...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin ...
It's not always a good thing when a drug developer stops a cancer trial. But in a recent case for Exelixis, a Cabometyx trial ended early because of an undeniable efficacy showing. In this study, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results